Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study - Aprepitant for cisplatin-induced delayed emesis

AZIENDA OSPEDALIERA S. MARIA DI TERNI0 个研究点目标入组 560 人开始时间: 2009年8月10日最近更新: 2012年4月3日

试验速览

暂无简介。

•- patients submitted for the first time to cisplatin chemotherapy administered in single dose
•- patients over 18 years old that signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- patients submitted on days 2-4 after cisplatin to other antineoplastic agents except 5-fluorouracil, VP16, VM26, vincristine, vinblastine, vindesine, vinorelbine, gemcitabine
•- patients already submitted to cisplatin
•- patients with serious disease or with predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, hypercalemia and brain metastases
•- patients with contraindications to dexamethasone administration (i.e. active peptic ulcer, previous blooding from peptic ulcer
•- patients receiving concomitant radiotherapy

发起方

AZIENDA OSPEDALIERA S. MARIA DI TERNI